Brown Advisory Inc. Has $30.40 Million Stake in Novartis AG (NVS)
Brown Advisory Inc. decreased its holdings in shares of Novartis AG (NYSE:NVS) by 2.3% during the third quarter, according to the company in its most recent disclosure with the SEC. The fund owned 354,147 shares of the company’s stock after selling 8,469 shares during the quarter. Brown Advisory Inc.’s holdings in Novartis were worth $30,403,000 at the end of the most recent reporting period.
Other institutional investors and hedge funds have also added to or reduced their stakes in the company. Parnassus Investments CA grew its stake in Novartis by 18.5% in the third quarter. Parnassus Investments CA now owns 9,447,817 shares of the company’s stock worth $811,095,000 after purchasing an additional 1,477,168 shares in the last quarter. Fisher Asset Management LLC grew its stake in Novartis by 2.0% in the third quarter. Fisher Asset Management LLC now owns 6,632,984 shares of the company’s stock worth $569,442,000 after purchasing an additional 127,049 shares in the last quarter. The Manufacturers Life Insurance Company grew its stake in Novartis by 3.1% in the second quarter. The Manufacturers Life Insurance Company now owns 5,036,427 shares of the company’s stock worth $420,390,000 after purchasing an additional 151,115 shares in the last quarter. BlackRock Inc. grew its stake in Novartis by 25.3% in the second quarter. BlackRock Inc. now owns 3,549,783 shares of the company’s stock worth $296,299,000 after purchasing an additional 717,186 shares in the last quarter. Finally, State Street Corp grew its stake in Novartis by 2.3% in the second quarter. State Street Corp now owns 3,046,276 shares of the company’s stock worth $254,273,000 after purchasing an additional 68,834 shares in the last quarter. 10.87% of the stock is currently owned by hedge funds and other institutional investors.
Novartis AG (NYSE NVS) traded up $0.25 during trading on Friday, reaching $86.05. The company’s stock had a trading volume of 1,178,747 shares, compared to its average volume of 1,344,384. The company has a debt-to-equity ratio of 0.32, a quick ratio of 0.81 and a current ratio of 1.08. The stock has a market capitalization of $202,968.06, a price-to-earnings ratio of 18.06, a P/E/G ratio of 2.74 and a beta of 0.73. Novartis AG has a one year low of $66.93 and a one year high of $86.90.
Several brokerages recently issued reports on NVS. J P Morgan Chase & Co reissued a “neutral” rating on shares of Novartis in a research note on Tuesday, October 31st. Zacks Investment Research raised Novartis from a “sell” rating to a “hold” rating in a research note on Thursday, October 26th. Barclays cut Novartis from an “equal weight” rating to an “underweight” rating in a research note on Wednesday, October 25th. Finally, Leerink Swann increased their price objective on Novartis from $89.00 to $91.00 and gave the stock a “market perform” rating in a research note on Monday, October 23rd. Three research analysts have rated the stock with a sell rating, ten have issued a hold rating and four have given a buy rating to the company. Novartis presently has a consensus rating of “Hold” and a consensus price target of $85.32.
COPYRIGHT VIOLATION NOTICE: This piece was published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this piece on another domain, it was illegally copied and reposted in violation of United States & international copyright law. The legal version of this piece can be accessed at https://www.thecerbatgem.com/2017/12/02/brown-advisory-inc-has-30-40-million-stake-in-novartis-ag-nvs.html.
Novartis Company Profile
Novartis AG is a holding company, which provides healthcare solutions. The Company is engaged in the research, development, manufacturing and marketing of a range of healthcare products led by pharmaceuticals. The Company’s segments include Innovative Medicines, Sandoz, Alcon and Corporate activities.
Receive News & Stock Ratings for Novartis AG Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novartis AG and related stocks with our FREE daily email newsletter.